Chen et al reported that in a cohort of stage III NSCLC patients in Chinese population receiving first-line platinum-based doublet chemotherapy, SLC31A1 protein overexpression is associated with better therapeutic response and better survival [16]. Here, SLC31A1 is linked to non-small cell lung carcinoma.